RxDoctor Payments Data

Eric Zhang

Optometrist · Diamond Bar, CANPI 1982282760

Payments from drug & device makers

$2,400in general payments, 2019–2025

Across 60 payments — averaging $40.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$626
  • Sun Pharmaceutical Industries Inc.$498
  • Dompe US, Inc.$485
  • Bausch & Lomb Americas Inc.$459
  • Johnson & Johnson$146
  • Amgen$91
  • plus $96 from 3 others

What the payments were for

  • Food & beverage$2,400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,400 in reported general payments places this provider in the 80th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$24,406
Medicare patients
106
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$27,197
Cyclosporine37$13,335
XiidraLifitegrast11$7,384
LumiganBimatoprost15$6,541
RhopressaNetarsudil Mesylate12$4,837
Latanoprost340$3,998
RocklatanNetarsudil Mesylat/Latanoprost11$3,409
Brimonidine Tartrate41$2,160
Azelastine Hcl58$1,095
Timolol Maleate98$768
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat68$740
Prednisolone Acetate27$577
Ketorolac Tromethamine18$301
Dorzolamide Hcl14$257
Ofloxacin27$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$459$7,38411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,778 optometrist providers in California.

Other optometrist in Diamond Bar

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →